Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
All news
Biotechnology
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). 29 November 2019
Biotechnology
Positive news results of the SAkuraSky Study, a global Phase III clinical study of satralizumab (development code: SA237) have published in the online version of The New England Journal of Medicine (NEJM). 29 November 2019
Biotechnology
Vancouver, Canada-based regenerative medicine company NervGen Pharma announced the appointment of Paul Brennan as president and chief executive effective immediately. 28 November 2019
Biotechnology
Nantes, France-based biotech OSE Immunotherapeutics has agreed a deal with immuno-oncology diagnostic firm HalioDx, to conduct a translational investigation of immune biomarkers. 28 November 2019
Biotechnology
The US Food and Drug Administration has accepted for Priority Review the New Drug Application (NDA) for pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with previously treated, locally-advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. 28 November 2019
Biotechnology
Researchers from Queen Mary University of London and Zhengzhou University, China, have developed a personalized vaccine system that could ultimately delay the onset of pancreatic cancer, they believe. 27 November 2019
Biotechnology
Singapore-based TauRx has announced the publication of unexpected results of its drug hydromethylthionine, or LMTM, in patients with mild-to-moderate Alzheimer's disease. 27 November 2019
Biotechnology
US drugmaker AbbVie frequently comes under fire for the money – well in excess of $100 billion – that it has earned from its mega blockbuster arthritis drug Humira (adalimumab). 27 November 2019
Biotechnology
The Roche majority-owned Chugai has launched the 840mg intravenous infusion of Tecentriq (atezollizumab) in Japan for the treatment of PD-L1-positive triple-negative breast cancer (TNBC). 27 November 2019
Biotechnology
Switzerland-based companies Lonza and DiNAQOR, a global gene therapy platform firm, have announced a strategic collaboration to advance the latter’s pre-clinical programs for the treatment of cardiac myosin-binding protein-C (MYBPC3) cardiomyopathies, a genetic condition that can result in heart failure. 27 November 2019
Biotechnology
US biotech firm Evofem Biosciences announced the resubmission of its New Drug Application to the US Food and Drug Administration for its lead candidate Amphora (L-lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy. 26 November 2019
Biotechnology
Shares in CymaBay Therapeutics closed 76% down on Monday after the company announced it was terminating its Phase IIb study of seladelpar in non-alcoholic steatohepatitis (NASH) and its recently initiated Phase II study of seladelpar in primary sclerosing cholangitis (PSC). 26 November 2019
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval to Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. 26 November 2019
Biotechnology
Canadian immuno-oncology specialist Medicenna Therapeutics has presented positive data from its Phase IIb trial of MDNA55 in people with recurrent glioblastoma (rGBM). 26 November 2019
Biotechnology
Privately-held Swiss drugmaker Ferring Pharmaceuticals has launched a new gene therapy company, FerGene, together with Blackstone Life Sciences. 25 November 2019
Biotechnology
The respiratory syncytial virus (RSV) market is expected to grow at a compound annual growth rate (CAGR) of 44.7% from $36.88 million in 2018 to $1.48 billion by 2028 across the five growth markets (5GM; Australia, India, Japan, South Korea and urban China) in the Asia-Pacific (APAC) region. 25 November 2019
Biotechnology
Full results from ERYTECH Pharma’s Phase IIb trial evaluating eryaspase in metastatic pancreatic cancer have now been published in the European Journal of Cancer. 25 November 2019
Biotechnology
Orchard Therapeutics has big ambitions for its role in pioneering some of the most advanced treatments in development today. 25 November 2019
Biotechnology
As is often the case, though not always, comments last week from ‘sources close to the negotiations’ have proved correct in the likely takeover by the Swiss pharma giant Novartis of USA-based The Medicines Company and its key novel siRNA candidate inclisiran, a biennial cholesterol-lowering drug now in Phase III testing. 25 November 2019
Biotechnology
Japan’s largest drugmaker Takeda Pharmaceutical presented updated data from the Phase III ALTA-1L trial, which evaluated Alunbrig (brigatinib) versus crizotinib (Pfizer’s [NYSE: PFE] Xalkori) in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor. 23 November 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze